GlaxoSmithKline Gets 79% Tenders for Human Genome Sciences Offer
30 Luglio 2012 - 3:06PM
Dow Jones News
LONDON--Research-based pharmaceutical and healthcare company
GlaxoSmithKline PLC (GSKl.LN) said Monday that the initial tender
offer for Human Genome Sciences Inc (HGSI) expired 0400 GMT on July
26, and at that time 158.61 million shares, or 79%, had been
validly tendered and not withdrawn.
MAIN FACTS:
-An additional 9.16 million Human Genome shares, or 4%, were
tendered subject to guaranteed delivery procedures.
-GlaxoSmithKline shares at 1235 GMT up 17 pence, or 1.14%, at
1460 pence valuing the company at 72.03 billion pounds.
-Write to Ian Walker at ian.walker@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Grafico Azioni Human Genome Sciences (NASDAQ:HGSI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Human Genome Sciences (NASDAQ:HGSI)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Human Genome Sciences, Inc. (MM) (NASDAQ): 0 articoli recenti
Più Human Genome Sciences Inc. Articoli Notizie